A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS 7)

• Status: Not yet recruiting
• Trial end date: 2026-02-10

Summary

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with gemcitabine, lenalidomide, polazutumab vedotin, or umbralisib, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.

• Phase: Phase 1

Details

• Lead Sponsor: ADC Therapeutics S.A.
• Treatments: Gemcitabine; Lenalidomide; Loncastuximab tesirine